gist

(redirected from gists)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to gists: GitHub

gist

the essential point of an action.

GIST, pleading. Gist of the action is the essential ground or object of it, in point of law, and without which there is no cause of action. Gould on Pl. c. 4, Sec. 12. But it is observable that the substance or gist of the action is not always the principal cause of the plaintiff Is complaint in point of fact, nor that on which he recovers all or the greatest part of his damages.
     2. It frequently happens that upon that part of his declaration which contains the substance or gist of the, action, he only recovers nominal damages, and he gets his principal satisfaction on account of matter altogether collateral thereto. A familiar instance of this is the case where a father sues the defendant for a trespass for the seduction of his daughter. The gist of the action is the trespass, and the loss of his daughter's services, but the collateral cause is the injury done to his feelings, for which the principal damages are given. In stating the substance or gist of the action, every thing must be averred which is necessary to be proved at the trial. Vide 1 Vin. Ab. 598; 2 Phil. Ev. 1, note. See Bac. Abr. Pleas, B; Doct. P. 85. See Damages, special, in pleading; 1 Vin. At. 598; 2 Phil. Ev. 1, n.

References in periodicals archive ?
Although gastrointestinal stromal tumors (GISTs) are a uncommon entity, prevalence in general population detected by abdominal ultrasonography is between 0.5 % and 5.0 % (Blanke & Corless, 2005; Blay et al., 2005; Heinrich & Corless, 2005).
A biopsy was performed, which confirmed the pathological diagnosis of GIST based on the prostatic tissue biopsy strips.
There was a mutatated KIT gene in 50% of the gastric GISTs, and in [greater than or equal to] 70% of the bowel and extravisceral GISTs.
Keywords: Gastrointestinal Stromal tumour (GIST ), Laparoscopic resection, Imatinib.
c-kit-mutated GIST. Almost 75% of all GISTs present gain-of-function mutations in the KIT gene in exons 11, 9, 13, and 17, which activate downstream pathways (RAS/RAF/MAPK, JAK/STAT3, and PI3K/AKT/mTOR), increasing proliferation or evading apoptosis.
Imatinib is the only approved first-line drug for gastrointestinal stromal tumor (GIST) patients, especially for patients with advanced or metastatic tumors (1,2).
The Ki-67 level was >7% in all patients with metastatic GISTs but in only 6 (54%) of the intermediate and high-risk patients.
Here we present a 68-year-old female, who was diagnosed with GIST. Pre-operatively, the patient underwent a CT abdomen with contrast.
Approximately 85% of GISTs are driven by activating mutations in the oncogenes KIT or alternatively PDGFRA , whereas this mutation of KIT and PDGFRA is very rare in NF1-GISTs.[3] Cases such as ours where various mutation types GISTs coexisting in a NF1 patient are rarer still.
Based on findings of this study it is recommended that all gastric GISTs below the age of 30 years with epithelioid morphology should be tested for SDH deficiency.
GISTs under endoscopic procedure typically form a well-delineated spherical or hemispheric mass, arising mostly from the muscularis propria (MP) layer beneath the mucosa and pushing it to the lumen to form a smooth contoured elevation (Figure 2).
EUS shows typical findings for some lesions, but in hypoechoic lesions, such as leiomyomas, GISTs, and schwannomas, EUS findings are not enough and EUS-Bs are needed.